文献速递呼吸衰竭与机械通气

GLPG1690(新型自分泌运动因子抑制剂)治疗特发性肺纤维化的安全性、耐受性、药代动力学与药效学(FLORA):一项2a期随机安慰剂对照试验

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.
PubMed 文献 · Lancet Respir Med · 2018-05-20
一句话结论在未用吡非尼酮或尼达尼布的IPF患者中,口服GLPG1690 600 mg每日一次共12周的安全性与安慰剂相似,血浆LPA C18:2持续下降,作者认为支持进一步开发。

FLORA是一项在意大利、乌克兰和英国17个中心开展的随机、双盲、安慰剂对照2a期研究,纳入40岁及以上、不吸烟、未服用吡非尼酮或尼达尼布且经中心确认诊断为IPF的患者,按1:3随机接受口服GLPG1690 600 mg每日一次或安慰剂共12周。实际入组23例(GLPG1690组17例、安慰剂组6例),来自8个中心(乌克兰6个、英国2个)。主要结局为安全性(不良事件)、耐受性、药代动力学和药效学;安慰剂组4例(67%)与GLPG1690组11例(65%)发生治疗中出现的不良事件,多为轻至中度,未报告死亡。药代动力学和药效学特征与既往健康对照相似,血浆LPA C18:2浓度持续下降;第12周用力肺活量较基线平均变化GLPG1690组为25 mL(95%CI -75至124),安慰剂组为-70 mL(95%CI -208至68 mL)。作者认为研究结果支持将GLPG1690作为IPF新型治疗进一步开发。

要点

  • 研究纳入未服用吡非尼酮或尼达尼布、经中心确认诊断的IPF患者,口服GLPG1690 600 mg每日一次共12周。
  • GLPG1690组17例中11例(65%)、安慰剂组6例中4例(67%)发生治疗中出现的不良事件,多为轻至中度。
  • GLPG1690组最常见不良事件为感染和侵染(10起)及呼吸、胸和纵隔疾病(8起),与安慰剂组无明显差异。
  • GLPG1690组2例(12%)不良事件被判定与治疗相关;安慰剂组2例、GLPG1690组1例发生严重不良事件,无患者死亡。
  • 血浆LPA C18:2浓度持续下降;第12周FVC较基线平均变化GLPG1690组25 mL(95%CI -75至124)vs 安慰剂组-70 mL(95%CI -208至68 mL)。

适用人群与场景

  • 年龄40岁及以上、不吸烟、未服用吡非尼酮或尼达尼布、经中心确认诊断为特发性肺纤维化的患者。
  • 研究在意大利、乌克兰和英国的17个中心开展,实际入组来自8个中心(乌克兰6个、英国2个)。

诊断标准与关键阈值

  • 入组要求经中心确认的特发性肺纤维化诊断。

处置流程与药物剂量

  • GLPG1690组:口服GLPG1690 600 mg每日一次,共12周。
  • 安慰剂组:口服安慰剂,共12周。

研究设计与关键结果

  • 研究类型:随机、双盲、安慰剂对照2a期研究,在意大利、乌克兰和英国的17个中心开展;2016年3月24日至2017年5月2日筛查72例,49例不合格,23例入组(8个中心:乌克兰6个、英国2个)。
  • 分组:按1:3随机接受安慰剂或GLPG1690 600 mg口服每日一次共12周,安慰剂组6例、GLPG1690组17例。
  • 完成情况:20例完成研究;每组各1例因不良事件中止,GLPG1690组另1例撤回知情同意。
  • 主要结局(安全性):安慰剂组4例(67%)与GLPG1690组11例(65%)发生治疗中出现的不良事件,多为轻至中度。
  • GLPG1690组最常见不良事件为感染和侵染(10起)及呼吸、胸和纵隔疾病(8起),与安慰剂组无明显差异;GLPG1690组2例(12%)不良事件被判定与治疗相关。
  • 严重不良事件:安慰剂组2例(1例尿路感染、急性肾损伤和下呼吸道感染,另1例二度房室传导阻滞),GLPG1690组1例(胆管癌,导致中止治疗);无患者死亡。
  • 药代动力学和药效学:GLPG1690的特征与既往健康对照相似,血浆LPA C18:2浓度持续下降。
  • 次要结局(肺功能):第12周FVC较基线平均变化GLPG1690组25 mL(95%CI -75至124)vs 安慰剂组-70 mL(95%CI -208至68 mL)。

证据类型、等级与局限

  • 证据类型:2a期随机、双盲、安慰剂对照试验。
  • 样本量小:共入组23例(GLPG1690组17例、安慰剂组6例)。
  • 作者结论为研究结果支持将GLPG1690作为特发性肺纤维化新型治疗进一步开发。

对床旁实践的改变

  • 作者认为研究结果支持将GLPG1690作为特发性肺纤维化新型治疗进一步开发。
  • 本研究为2a期小样本研究,原文未据此给出临床用药推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function. People with IPF have increased concentrations of autotaxin in lung tissue and lysophosphatidic acid (LPA) in bronchoalveolar lavage fluid and exhaled condensate. GLPG1690 (Galapagos, Mechelen, Belgium) is a novel, potent, selective autotaxin inhibitor with good oral exposure. We explored the effects of GLPG1690 in patients with IPF.

METHODS: This was a randomised, double-blind, placebo-controlled phase 2a study done in 17 centres in Italy, Ukraine and the UK. Eligible patients were aged 40 years or older, non-smokers, not taking pirfenidone or nintedanib, and had a centrally confirmed diagnosis of IPF. We used a computer-generated randomisation schedule to assign patients 1:3 to receive placebo or 600 mg oral GLPG1690 once daily for 12 weeks. The primary outcomes were safety (adverse events), tolerability, pharmacokinetics, and pharmacodynamics. Spirometry was assessed as a secondary outcome. This trial is registered with ClinicalTrials.gov, number NCT02738801.

FINDINGS: Between March 24, 2016, and May 2, 2017, 72 patients were screened., of whom 49 were ineligible and 23 were enrolled in eight centres (six in Ukraine and two in the UK). Six patients were assigned to receive placebo and 17 to receive GLPG1690. 20 patients completed the study after one in each group discontinued because of adverse events and one in the GLPG1690 group withdrew consent. Four (67%) patients in the placebo group and 11 (65%) in the GLPG1690 group had treatment-emergent adverse events, most of which were mild to moderate. The most frequent events in the GLPG1690 group were infections and infestations (ten events) and respiratory, thoracic, and mediastinal disorders (eight events) with no apparent differences from the placebo group. Two (12%) patients in the GLPG1690 group had events that were judged to be related to treatment. Serious adverse events were seen in two patients in the placebo group (one had a urinary tract infection, acute kidney injury, and lower respiratory tract infection and the other had atrioventricular block, second degree) and one in the GLPG1690 group (cholangiocarcinoma that resulted in discontinuation of treatment). No patients died. The pharmacokinetic and pharmacodynamic profiles of GLPG1690 were similar to those previously shown in healthy controls. LPA C18:2 concentrations in plasma were consistently decreased. Mean change from baseline in forced vital capacity at week 12 was 25 mL (95% CI -75 to 124) for GLPG1690 and -70 mL (-208 to 68 mL) for placebo.

INTERPRETATION: Our findings support further development of GLPG1690 as a novel treatment for IPF.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Maher TM, van der Aar EM, Van de Steen O, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018. PMID: 29792287. doi:10.1016/S2213-2600(18)30181-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。